Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 36NET 23Gastrointestinal 23Thoracic 5Head & Neck 5Sarcoma 4Genitourinary 4CNS 4Dermatologic 3Breast 2Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 184Mesothelioma, Malignant 183Mesothelioma 145Solid Tumor 135Retinoblastoma 96Solid Tumors 86Advanced Solid Tumor 60Advanced Solid Tumors 50Solid Tumor, Adult 47Hematopoietic and Lymphatic System Neoplasm 47Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 33Sarcoma 28Hematopoietic and Lymphoid System Neoplasm 23Small Cell Lung Carcinoma 21Pancreatic Neoplasms 20Stomach Neoplasms 19Neuroblastoma 19Melanoma 19Carcinoma, Renal Cell 19Ovarian Neoplasms 18Neoplasms 17Wilms Tumor 15Colorectal Neoplasms 15Breast Neoplasms 15Osteosarcoma 13Solitary Fibrous Tumor, Pleural 12Rhabdomyosarcoma 12Refractory Solid Tumors 12Esophageal Neoplasms 12

Interventions

atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Islet Cell × Other solid neoplasm × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡